Literature DB >> 16402217

Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events.

L Konttinen1, V Honkanen, T Uotila, J Pöllänen, M Waahtera, M Romu, K Puolakka, M Vasala, A Karjalainen, R Luukkainen, D C Nordström.   

Abstract

The objective of this study was to assess the long-term safety and tolerability of biologicals in a clinical setting. Data on adverse events (AEs) have been collected over a 5-year period by means of detailed reports sent in to the National Register of Biological Treatment in Finland (ROB-FIN) and validated by information collected by the National Agency for Medicines. Three hundred and eight reports on AEs were filed, concerning a total of 248 patients; this corresponds to 17% of all patients in the ROB-FIN register who started biological treatments. Skin reactions and infections comprised 35 and 28% of the AEs, respectively. Some cases of tuberculosis and other infections, heart failure and demyelinating conditions were seen. Our work demonstrates no unexpected AEs in a Finnish patient cohort consisting of rheumatoid arthritis and spondylarthropathy patients, although many of them were treated with combination treatments in common use in Finland. Biological treatment appears safe in the hands of the Finnish rheumatologists.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16402217     DOI： 10.1007/s00296-005-0097-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  31 in total

Review 1.  Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

Authors:  W H Robinson; M C Genovese; L W Moreland
Journal:  Arthritis Rheum       Date:  2001-09

Review 2.  Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer.

Authors:  Deborah P M Symmons; Alan J Silman
Journal:  Arthritis Rheum       Date:  2004-06

3.  Onset of multiple sclerosis associated with anti-TNF therapy.

Authors:  N L Sicotte; R R Voskuhl
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

4.  Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis.

Authors:  H A Isomäki; T Hakulinen; U Joutsenlahti
Journal:  J Chronic Dis       Date:  1978

5.  Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

Authors:  Timo Möttönen; Pekka Hannonen; Markku Korpela; Martti Nissilä; Hannu Kautiainen; Jorma Ilonen; Leena Laasonen; Oili Kaipiainen-Seppänen; Per Franzen; Tapani Helve; Juhani Koski; Marianne Gripenberg-Gahmberg; Riitta Myllykangas-Luosujärvi; Marjatta Leirisalo-Repo
Journal:  Arthritis Rheum       Date:  2002-04

6.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

7.  Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.

Authors:  P Geborek; A Bladström; C Turesson; A Gulfe; I F Petersson; T Saxne; H Olsson; L T H Jacobsson
Journal:  Ann Rheum Dis       Date:  2005-02-04       Impact factor: 19.103

8.  Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.

Authors:  Kari Puolakka; Hannu Kautiainen; Timo Möttönen; Pekka Hannonen; Markku Korpela; Markku Hakala; Pentti Järvinen; Jari Ahonen; Sinikka Forsberg; Marjatta Leirisalo-Repo
Journal:  Arthritis Rheum       Date:  2005-01

9.  Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

Authors:  P Geborek; M Crnkic; I F Petersson; T Saxne
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

10.  Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee.

Authors:  E L Matteson; A R Hickey; L Maguire; H H Tilson; M B Urowitz
Journal:  J Rheumatol       Date:  1991-06       Impact factor: 4.666
View more
  6 in total

1.  Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).

Authors:  Liisa M Virkki; Heikki Valleala; Yuya Takakubo; Jorma Vuotila; Heikki Relas; Riitta Komulainen; Riitta Koivuniemi; Urpo Yli-Kerttula; Markku Mali; Susanna Sihvonen; Maija-Liisa Krogerus; Eero Jukka; Satu Nyrhinen; Yrjö T Konttinen; Dan C Nordström
Journal:  Clin Rheumatol       Date:  2011-06-07       Impact factor: 2.980

2.  Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience.

Authors:  Liisa Konttinen; Riitta Tuompo; Tea Uusitalo; Riitta Luosujärvi; Kari Laiho; Jukka Lähteenmäki; Maija Puurtinen-Vilkki; Ritva Lanteri; Saara Kortelainen; Helena Karilainen; Tuire Varjolahti-Lehtinen; Dan Nordström
Journal:  Clin Rheumatol       Date:  2007-03-01       Impact factor: 2.980

3.  Discontinuation of anti-TNF-α therapy in a Chinese cohort of patients with rheumatoid arthritis.

Authors:  Cheng-Tao Yang; Chang-Fu Kuo; Shue-Fen Luo; Kuang-Hui Yu
Journal:  Clin Rheumatol       Date:  2012-07-31       Impact factor: 2.980

4.  Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years' drug survival.

Authors:  Tiina Levälampi; Markku Korpela; Katriina Vuolteenaho; Eeva Moilanen
Journal:  Rheumatol Int       Date:  2009-10-10       Impact factor: 2.631

5.  Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment.

Authors:  Tiina Levälampi; Markku Korpela; Katriina Vuolteenaho; Eeva Moilanen
Journal:  Rheumatol Int       Date:  2007-09-06       Impact factor: 2.631

Review 6.  Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example.

Authors:  Katerina Chatzidionysiou; Merete Lund Hetland; Thomas Frisell; Daniela Di Giuseppe; Karin Hellgren; Bente Glintborg; Dan Nordström; Kalle Aaltonen; Minna Rk Törmänen; Eirik Klami Kristianslund; Tore K Kvien; Sella A Provan; Bjorn Björn Guðbjörnsson; Lene Dreyer; Lars Erik Kristensen; Tanja Schjødt Jørgensen; Lennart Jacobsson; Johan Askling
Journal:  RMD Open       Date:  2018-04-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.